{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:15:16Z","timestamp":1788225316134,"version":"build-2803163510"},"reference-count":27,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2026,2,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>In Tuberculosis Trials Consortium Study 35, which investigated the optimal dosing and safety of once-weekly isoniazid and rifapentine (3HP) in 69 children requiring tuberculosis preventive therapy, 7 children with HIV received 50 mg of once-daily dolutegravir. Plasma dolutegravir concentrations were consistent with those predicted in children on dolutegravir not receiving 3HP or potential metabolic inducers. All participants maintained viral suppression. Despite the expected induction effect of 3HP, results suggest that dolutegravir dose adjustments are not required.<\/jats:p>\n                    <jats:sec>\n                      <jats:title>IMPORTANCE<\/jats:title>\n                      <jats:p>This work describes the observed concentrations of dolutegravir in children co-administering rifapentine and dolutegravir. The work compares these concentrations with the model-simulated concentrations of a model developed using children not taking rifapentine or other metabolically inducing agents but who were administering dolutegravir. These data are the first available in children and are valuable in understanding the interaction of dolutegravir and rifapentine in children.<\/jats:p>\n                    <\/jats:sec>\n                    <jats:sec>\n                      <jats:title>CLINICAL TRIALS<\/jats:title>\n                      <jats:p>\n                        This study is registered with the Tuberculosis Trials Consortium Study 35 as\n                        <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03730181\" xlink:type=\"simple\">NCT03730181<\/jats:ext-link>\n                        .\n                      <\/jats:p>\n                    <\/jats:sec>\n                  <\/jats:sec>","DOI":"10.1128\/spectrum.03303-25","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T14:00:11Z","timestamp":1767880811000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["Dolutegravir concentrations in children receiving 3-month weekly isoniazid and rifapentine (3HP) for tuberculosis prevention"],"prefix":"10.1128","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9136-7657","authenticated-orcid":true,"given":"Ruvarashe J.","family":"Madzime","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03p74gp79","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town","place":["Rondebosch, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3584-7477","authenticated-orcid":true,"given":"Louvina","family":"van der Laan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05bk57929","id-type":"ROR","asserted-by":"publisher"}],"name":"Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University","place":["Stellenbosch, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"du Toit","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05bk57929","id-type":"ROR","asserted-by":"publisher"}],"name":"FAMCRU, Department of Paediatrics and Child Health Faculty of Medicine and Health Sciences, Stellenbosch University","place":["Stellenbosch, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Barnabas","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05bk57929","id-type":"ROR","asserted-by":"publisher"}],"name":"FAMCRU, Department of Paediatrics and Child Health Faculty of Medicine and Health Sciences, Stellenbosch University","place":["Stellenbosch, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Courtney","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05bk57929","id-type":"ROR","asserted-by":"publisher"}],"name":"Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University","place":["Stellenbosch, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole E.","family":"Brown","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00qzjvm58","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Tuberculosis Elimination, Centers for Disease Control and Prevention (CDC)","place":["Atlanta, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rada","family":"Savic","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/029m7xn54","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Bioengineering and Therapeutic Sciences, University of San Francisco Schools of Pharmacy and Medicine","place":["San Francisco, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4621-5480","authenticated-orcid":true,"given":"Belen P.","family":"Solans","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/029m7xn54","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Bioengineering and Therapeutic Sciences, University of San Francisco Schools of Pharmacy and Medicine","place":["San Francisco, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith G.","family":"Dixon","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00qzjvm58","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Tuberculosis Elimination, Centers for Disease Control and Prevention (CDC)","place":["Atlanta, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lufina","family":"Tsirizani","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03p74gp79","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town","place":["Rondebosch, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7494-079X","authenticated-orcid":true,"given":"Paolo","family":"Denti","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03p74gp79","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town","place":["Rondebosch, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Boyd","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00qzjvm58","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Tuberculosis Elimination, Centers for Disease Control and Prevention (CDC)","place":["Atlanta, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9399-9834","authenticated-orcid":true,"given":"Anneke C.","family":"Hesseling","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05bk57929","id-type":"ROR","asserted-by":"publisher"}],"name":"Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University","place":["Stellenbosch, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the TBTC Study 35 team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","unstructured":"World Health Organization. 2018. Policy brief: updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: HIV treatment interim guidance. World Health Organization. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/273632. Retrieved 23 Jan 2025."},{"key":"e_1_3_4_3_2","unstructured":"World Health Organization. 2021. Consolidated guidelines on HIV prevention testing treatment service delivery and monitoring: recommendations for a public health approach. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240031593. Retrieved 22 Jan 2025."},{"key":"e_1_3_4_4_2","volume-title":"Global tuberculosis report 2023","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. 2023. Global tuberculosis report 2023. https:\/\/iris.who.int."},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104875"},{"key":"e_1_3_4_6_2","volume-title":"WHO consolidated guidelines on tuberculosis. Module 1: prevention - tuberculosis preventive treatment","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. 2024. WHO consolidated guidelines on tuberculosis. Module 1: prevention - tuberculosis preventive treatment. 2nd ed. https:\/\/www.who.int\/publications\/i\/item\/9789240096196.","edition":"2"},{"key":"e_1_3_4_7_2","volume-title":"WHO operational handbook on tuberculosis. Module 1: prevention - tuberculosis preventive treatment","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. 2024. WHO operational handbook on tuberculosis. Module 1: prevention - tuberculosis preventive treatment. 2nd ed. https:\/\/www.who.int\/publications\/i\/item\/9789240097773.","edition":"2"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.03947.x"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.323"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy082"},{"key":"e_1_3_4_11_2","unstructured":"IMPAACT4TB\u202f: The Aurum Institute 2019. 3HP drug-drug interactions including ART. Available from: https:\/\/www.impaact4tb.org\/wp-content\/uploads\/2020\/04\/5T-eng-DDI-Drugs-Drug-Interactions-Art_RB16.pdf. Retrieved 09 Jun 2025."},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318276cda9"},{"key":"e_1_3_4_13_2","unstructured":"National Institutes of Health HIV Medicine Association and Infectious Diseases Society of America. 2025. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Available from: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-opportunistic-infection. Retrieved 09 Jun 2025."},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(25)00002-5"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piae076"},{"key":"e_1_3_4_16_2","unstructured":"R Core Team. 2024. R: a language and environment for statistical computing. Available from: https:\/\/www.R-project.org\/. Retrieved 30 May 2024."},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-2607(98)00067-4"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.24"},{"key":"e_1_3_4_19_2","unstructured":"ICON. 2024. NONMEM: non-linear fixed effects modelling tool. Available from: https:\/\/www.iconplc.com\/solutions\/technologies\/nonmem. Retrieved 30 May 2024."},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00842-09"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32834a1dd9"},{"key":"e_1_3_4_22_2","first-page":"437","article-title":"Single and multiple dose pharmacokinetics of rifapentine in man: part II","volume":"3","author":"Keung A","year":"1999","unstructured":"Keung A, Eller MG, McKenzie KA, Weir SJ. 1999. Single and multiple dose pharmacokinetics of rifapentine in man: part II. Int J Tuberc Lung Dis 3:437\u2013444.","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.34.1026"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200311-1612OC"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-385471-1.00015-5"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.115.065326"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30032-1"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00081-4"}],"container-title":["Microbiology Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.03303-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.03303-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:47:00Z","timestamp":1788223620000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/spectrum.03303-25"}},"subtitle":[],"editor":[{"given":"Rafael A.","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,3]]}},"alternative-id":["10.1128\/spectrum.03303-25"],"URL":"https:\/\/doi.org\/10.1128\/spectrum.03303-25","relation":{},"ISSN":["2165-0497"],"issn-type":[{"value":"2165-0497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"2025-10-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e03303-25"}}